 Gwendolyn Kerby
Concepts (147)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tobacco Smoke Pollution | 7 | 2023 | 261 | 0.950 |
Why?
| | Cystic Fibrosis | 10 | 2018 | 1114 | 0.800 |
Why?
| | Respiratory Function Tests | 8 | 2015 | 600 | 0.740 |
Why?
| | Smoking Cessation | 4 | 2022 | 442 | 0.510 |
Why?
| | Pseudomonas Infections | 2 | 2018 | 225 | 0.440 |
Why?
| | Spirometry | 4 | 2012 | 281 | 0.420 |
Why?
| | Neuroendocrine Cells | 1 | 2012 | 32 | 0.390 |
Why?
| | Cough | 3 | 2013 | 122 | 0.390 |
Why?
| | Plethysmography | 4 | 2012 | 106 | 0.300 |
Why?
| | Lung | 4 | 2015 | 4060 | 0.280 |
Why?
| | Cotinine | 3 | 2021 | 77 | 0.250 |
Why?
| | Lung Diseases, Interstitial | 1 | 2012 | 638 | 0.250 |
Why?
| | Child, Preschool | 13 | 2022 | 11074 | 0.210 |
Why?
| | Prednisone | 2 | 2019 | 240 | 0.210 |
Why?
| | Sodium Chloride | 2 | 2015 | 142 | 0.210 |
Why?
| | Dexamethasone | 2 | 2019 | 368 | 0.190 |
Why?
| | Pediatricians | 1 | 2023 | 129 | 0.190 |
Why?
| | Motivational Interviewing | 1 | 2023 | 107 | 0.190 |
Why?
| | Forced Expiratory Volume | 4 | 2015 | 531 | 0.190 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2002 | 162 | 0.190 |
Why?
| | Child, Hospitalized | 2 | 2020 | 49 | 0.190 |
Why?
| | Oscillometry | 2 | 2011 | 42 | 0.180 |
Why?
| | Respiratory Physiological Phenomena | 1 | 2021 | 31 | 0.170 |
Why?
| | Hospitals, Pediatric | 3 | 2019 | 508 | 0.170 |
Why?
| | Information Systems | 1 | 2021 | 61 | 0.170 |
Why?
| | Electronic Health Records | 2 | 2021 | 1069 | 0.170 |
Why?
| | Sample Size | 1 | 2010 | 125 | 0.170 |
Why?
| | Parents | 4 | 2021 | 1347 | 0.150 |
Why?
| | Infant | 11 | 2022 | 9465 | 0.150 |
Why?
| | Azithromycin | 1 | 2018 | 100 | 0.140 |
Why?
| | Bronchoscopy | 2 | 2016 | 223 | 0.130 |
Why?
| | Clinical Trials as Topic | 2 | 2011 | 1050 | 0.120 |
Why?
| | Child | 12 | 2023 | 21935 | 0.110 |
Why?
| | Macrophages | 1 | 2002 | 1547 | 0.110 |
Why?
| | Pseudomonas aeruginosa | 2 | 2018 | 352 | 0.110 |
Why?
| | Environmental Exposure | 1 | 2018 | 579 | 0.110 |
Why?
| | Saline Solution, Hypertonic | 1 | 2012 | 41 | 0.100 |
Why?
| | Male | 16 | 2023 | 67762 | 0.100 |
Why?
| | Hyperplasia | 1 | 2012 | 175 | 0.090 |
Why?
| | Humans | 21 | 2023 | 137585 | 0.090 |
Why?
| | Asthma | 2 | 2019 | 2295 | 0.090 |
Why?
| | Cross-Sectional Studies | 2 | 2012 | 5472 | 0.090 |
Why?
| | Feasibility Studies | 2 | 2011 | 956 | 0.080 |
Why?
| | Patient Readmission | 1 | 2016 | 697 | 0.080 |
Why?
| | Anti-Bacterial Agents | 2 | 2018 | 1809 | 0.080 |
Why?
| | Colorado | 3 | 2020 | 4565 | 0.080 |
Why?
| | Practice Patterns, Physicians' | 1 | 2019 | 1313 | 0.080 |
Why?
| | Longitudinal Studies | 3 | 2013 | 2844 | 0.080 |
Why?
| | Sensitivity and Specificity | 2 | 2011 | 1946 | 0.080 |
Why?
| | Smoking Prevention | 2 | 2021 | 184 | 0.080 |
Why?
| | Female | 14 | 2023 | 73304 | 0.080 |
Why?
| | Reproducibility of Results | 3 | 2013 | 3284 | 0.080 |
Why?
| | Smoking | 3 | 2021 | 1627 | 0.070 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2011 | 329 | 0.070 |
Why?
| | Follow-Up Studies | 3 | 2012 | 5131 | 0.070 |
Why?
| | Inpatients | 2 | 2022 | 500 | 0.070 |
Why?
| | Administration, Inhalation | 3 | 2018 | 688 | 0.060 |
Why?
| | Caregivers | 2 | 2023 | 877 | 0.060 |
Why?
| | Double-Blind Method | 3 | 2018 | 1993 | 0.060 |
Why?
| | Postoperative Complications | 1 | 2016 | 2654 | 0.050 |
Why?
| | Case-Control Studies | 1 | 2011 | 3556 | 0.050 |
Why?
| | Glucocorticoids | 1 | 2008 | 594 | 0.050 |
Why?
| | Adolescent | 6 | 2022 | 21513 | 0.050 |
Why?
| | MAP Kinase Kinase 4 | 1 | 2002 | 29 | 0.050 |
Why?
| | Chromones | 1 | 2002 | 44 | 0.050 |
Why?
| | Osmotic Pressure | 1 | 2002 | 38 | 0.050 |
Why?
| | Mice, Inbred C3H | 1 | 2002 | 269 | 0.050 |
Why?
| | Flavonoids | 1 | 2002 | 85 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2002 | 134 | 0.050 |
Why?
| | Beclomethasone | 1 | 2001 | 27 | 0.050 |
Why?
| | Morpholines | 1 | 2002 | 122 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2002 | 185 | 0.050 |
Why?
| | Adrenal Glands | 1 | 2001 | 78 | 0.050 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2002 | 283 | 0.040 |
Why?
| | Single-Blind Method | 1 | 2021 | 282 | 0.040 |
Why?
| | Cohort Studies | 1 | 2011 | 5742 | 0.040 |
Why?
| | Recurrence | 2 | 2018 | 1060 | 0.040 |
Why?
| | Drug Administration Schedule | 2 | 2019 | 786 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2002 | 313 | 0.040 |
Why?
| | Interleukin-8 | 1 | 2001 | 268 | 0.040 |
Why?
| | Counseling | 1 | 2023 | 391 | 0.040 |
Why?
| | MAP Kinase Signaling System | 1 | 2002 | 320 | 0.040 |
Why?
| | Tobacco Use | 1 | 2020 | 64 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2002 | 437 | 0.040 |
Why?
| | Pulmonologists | 1 | 2019 | 14 | 0.040 |
Why?
| | Vital Capacity | 1 | 2010 | 311 | 0.040 |
Why?
| | Symptom Flare Up | 1 | 2019 | 39 | 0.040 |
Why?
| | Tobacco Products | 1 | 2020 | 138 | 0.040 |
Why?
| | Drug Substitution | 1 | 2019 | 54 | 0.040 |
Why?
| | Cell Survival | 1 | 2002 | 1120 | 0.040 |
Why?
| | Reference Values | 1 | 2010 | 816 | 0.040 |
Why?
| | Retrospective Studies | 2 | 2016 | 15657 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2002 | 840 | 0.040 |
Why?
| | Proto-Oncogene Proteins | 1 | 2002 | 648 | 0.040 |
Why?
| | Tobramycin | 1 | 2018 | 52 | 0.040 |
Why?
| | Directive Counseling | 1 | 2018 | 47 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2001 | 513 | 0.040 |
Why?
| | Anti-Inflammatory Agents | 1 | 2001 | 496 | 0.030 |
Why?
| | Family | 1 | 2022 | 671 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2002 | 1242 | 0.030 |
Why?
| | Treatment Outcome | 4 | 2018 | 10811 | 0.030 |
Why?
| | Pneumonia | 1 | 2002 | 639 | 0.030 |
Why?
| | Prospective Studies | 4 | 2012 | 7604 | 0.030 |
Why?
| | Consensus | 1 | 2019 | 683 | 0.030 |
Why?
| | Dimensional Measurement Accuracy | 1 | 2015 | 13 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2018 | 1066 | 0.030 |
Why?
| | Pediatrics | 1 | 2023 | 1101 | 0.030 |
Why?
| | Hospitalists | 1 | 2019 | 245 | 0.030 |
Why?
| | Self Report | 1 | 2019 | 827 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2002 | 4193 | 0.030 |
Why?
| | Social Support | 1 | 2018 | 618 | 0.030 |
Why?
| | Statistics, Nonparametric | 2 | 2008 | 431 | 0.030 |
Why?
| | Functional Residual Capacity | 1 | 2013 | 8 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2001 | 2833 | 0.030 |
Why?
| | Apoptosis | 1 | 2002 | 2553 | 0.030 |
Why?
| | Emergency Service, Hospital | 2 | 2019 | 2069 | 0.030 |
Why?
| | Young Adult | 2 | 2020 | 13209 | 0.020 |
Why?
| | Adult | 3 | 2020 | 37929 | 0.020 |
Why?
| | Isotonic Solutions | 1 | 2012 | 38 | 0.020 |
Why?
| | Radiography, Thoracic | 1 | 2013 | 167 | 0.020 |
Why?
| | Age Factors | 1 | 2019 | 3295 | 0.020 |
Why?
| | Clinical Competence | 1 | 2019 | 1118 | 0.020 |
Why?
| | Body Height | 1 | 2012 | 199 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2828 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2022 | 6079 | 0.020 |
Why?
| | United States | 2 | 2021 | 14841 | 0.020 |
Why?
| | Hospitalization | 1 | 2019 | 2199 | 0.020 |
Why?
| | Staphylococcus aureus | 1 | 2013 | 450 | 0.020 |
Why?
| | Staphylococcal Infections | 1 | 2013 | 400 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2010 | 7635 | 0.020 |
Why?
| | Body Weight | 1 | 2012 | 985 | 0.020 |
Why?
| | Time Factors | 1 | 2018 | 6828 | 0.020 |
Why?
| | Middle Aged | 2 | 2018 | 33479 | 0.020 |
Why?
| | Quality Improvement | 1 | 2016 | 1178 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 530 | 0.020 |
Why?
| | Administration, Oral | 1 | 2008 | 816 | 0.020 |
Why?
| | Mice | 1 | 2002 | 17787 | 0.010 |
Why?
| | Risk Factors | 1 | 2016 | 10388 | 0.010 |
Why?
| | Airway Resistance | 1 | 2001 | 41 | 0.010 |
Why?
| | Nebulizers and Vaporizers | 1 | 2001 | 86 | 0.010 |
Why?
| | Probability | 1 | 2001 | 304 | 0.010 |
Why?
| | Aged | 1 | 2010 | 23961 | 0.010 |
Why?
| | Animals | 1 | 2002 | 36940 | 0.010 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2001 | 652 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2001 | 1316 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2001 | 2057 | 0.010 |
Why?
| | Pilot Projects | 1 | 2001 | 1710 | 0.010 |
Why?
|
|
Kerby's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|